Despite near-term Restasis headwind, Allergan's defensible products and pipeline support growth.
Overall, Allergan’s third-quarter results continue to mostly track our expectations, and we don’t anticipate a change in our fair value estimate or wide moat rating. Following the recent invalidation of Restasis’ patents and Teva’s weak stock price, we weren’t surprised to see Allergan recognize $3.4 billion and $1.3 billion in respective impairments related to these issues. While we think the market remains overly focused on near-term generic competition on a handful of products in 2018, especi...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.